prof. xavier monnet

54
Prof. Xavier MONNET Medical Intensive Care Unit Bicêtre Hospital Assistance publique – Hôpitaux de Paris FRANCE Assessment of fluid therapy Use the right tool for the right job!

Upload: karik

Post on 23-Feb-2016

84 views

Category:

Documents


1 download

DESCRIPTION

Assessment of fluid therapy Use the right tool for the right job!. Prof. Xavier MONNET. Medical Intensive Care Unit Bicêtre Hospital Assistance publique – Hôpitaux de Paris FRANCE. Conflict of interest. Pulsion Medical Systems. Assessment of fluid therapy - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Prof. Xavier MONNET

Prof. Xavier MONNET

Medical Intensive Care UnitBicêtre Hospital

Assistance publique – Hôpitaux de ParisFRANCE

Assessment of fluid therapy

Use the right tool for the right job!

Page 2: Prof. Xavier MONNET

Conflict of interest

Pulsion Medical Systems

Page 3: Prof. Xavier MONNET

Prof. Xavier MONNET

Medical Intensive Care UnitBicêtre Hospital

Assistance publique – Hôpitaux de ParisFRANCE

Assessment of fluid therapy

Use the right tool for the right job!

Page 4: Prof. Xavier MONNET

APCVP

PiCCO

EsophagealDoppler

Echo

ProAQT/PulsioFlex

PAC

FloTrac/Vigileo

Nexfin

Differents monitoring devicesDifferent indications ?

Page 5: Prof. Xavier MONNET
Page 6: Prof. Xavier MONNET

Peri-op monitoring

ICU monitoring

Pe

ri-op

mon

itorin

g

Page 7: Prof. Xavier MONNET

Context

Goals of monitoring

Improves prognosis

to detect hemodynamic deterioration

to guide volume expansion

High-risk surgical patients (except cardiac surgery)

Peri-

op m

onito

ring

Page 8: Prof. Xavier MONNET

60 patients hip replacement

hospital length of stay

100 high-risksurgical patients

hospital length of stay

174 patients post cardiac surgery

hospital length of stay

162 multiple trauma patientsafter surgery

hospital length of stay ICU length of stay lactate levelPe

ri-op

mon

itorin

g Improves prognosis with esophageal Doppler

Page 9: Prof. Xavier MONNET

60-risk general surgical patientsGoal directed therapy vs. conventional treatmentPost-operative phase

Peri-

op m

onito

ring

number of complications hospital length of stay

120 high-risk abdominalsurgery patientsSVV-directed therapy vs. conventional treatmentPer-operative phaseLidCO monitoring

number of complications hospital length of stay

Improves prognosis with LidCO

Page 10: Prof. Xavier MONNET

40 patients with hip replacement under regional anesthesiaGoal directed therapy vs. conventional treatment

Peri-

op m

onito

ring

number of complications

Improves prognosis with Flotrac/Vigileo

Page 11: Prof. Xavier MONNET

Vigileo Eso Doppler

preloaddependance

(Δ aortic blood flow)

preload(FTc)

Pulsioflex

preloaddependance

(VVE and Δ PP)

preloaddependance

(VVE and Δ PP)

LidCOrapid

preloaddependance

(VVE and Δ PP)

continuouscardiac output

continuouscardiac output(cardiac output)(AP curve

analysis)

continuouscardiac output(AP curve analysis)

continuouscardiac output(AP curve analysis)

Peri-

op m

onito

ring

Page 12: Prof. Xavier MONNET

Arterial pressure

Esophageal Doppler

Flotrac/VigileoPulsioflex

LidCOrapid

PA catheter

CVP

PiCCOEV 1000

ICU monitoringOR monitoring

Basic monitoring Advanced monitoring

Page 13: Prof. Xavier MONNET

Context

Objectives of monitoring

initial phase of shock

after the ER

assess the hemodynamic profile (type of shock)

guide initial therapy

fix some therapeutic goals

Which basic monitoring?Basic

ICU

mon

itorin

g

Page 14: Prof. Xavier MONNET

Basic

ICU

mon

itorin

g

Page 15: Prof. Xavier MONNET

Helps for :Helps for:

determining the type of shock(preload)

guiding fluid responsiveness(preload)

CVP Arterial pressure

deciding to give vasopressors

deciding to give fluid(if ventilated)

fixing some therapeutic goals

Basic

ICU

mon

itorin

g

DAP

PPV

MAP

Page 16: Prof. Xavier MONNET

Arterial pressure

Esophageal Doppler

Flotrac/VigileoPulsioflex

LidCOrapid

PA catheter

CVP

PiCCOEV 1000

ICU monitoring

OR monitoring

Basic monitoring Advanced monitoring

?

?

Page 17: Prof. Xavier MONNET

The only arterial pressure and CVP monitoring is not sufficient anymore

critically ill patients

Context

because patients receive vasopressors

Adva

nced

ICU

mon

itorin

g

when shock persists after initial fluid therapy

Page 18: Prof. Xavier MONNET

r = 0.56n = 228

r = 0.21n = 145

*

-50 0 50 100 150 200 250 300-50

0

50

100

150

200

250

300

Changes in CI induced by VE (%)

Changes in PPinduced by VE (%)

-50 0 50 100 150 200 250 300-50

0

50

100

150

200

250

300

Changes in CI induced by NE (%)

Changes in PPinduced by NE (%)

228 pts receiving volume expansion145 patients with increase of NE

Adva

nced

ICU

mon

itorin

g

Page 19: Prof. Xavier MONNET

-20

0

20

40

60

80

100

non responders responders

changes in CI (%)

-20

0

20

40

60

80

100

non responders responders

changes in PP (%)

+15%

6% false +

228 pts receiving volume expansion145 patients with increase of NE

22% false -

Adva

nced

ICU

mon

itorin

g

Page 20: Prof. Xavier MONNET

Adva

nced

ICU

mon

itorin

gVigileo Eso Doppler

preloaddependance

(Δ aortic blood flow)

preload(FTc)

Pulsioflex

preloaddependance

(VVE and Δ PP)

preloaddependance

(VVE and Δ PP)

LidCOrapid

preloaddependance

(VVE and Δ PP)

continuouscardiac output

continuouscardiac output(cardiac output)(AP curve

analysis)

continuouscardiac output(AP curve analysis)

continuouscardiac output(AP curve analysis)

continuouscardiac output

AP curve analysis

uncalibrated

continuouscardiac output

AP curve analysis

uncalibrated

continuouscardiac output

AP curveanalysis

uncalibrated

Page 21: Prof. Xavier MONNET

20

40

60

80

100

120

0

= k . SV

Uncalibrated devices

estimate SV from the arterial pressure curve

estimate arterial compliance by analysing the arterial waveform

?still valuable when the properties of the arterial curve

change in a large extent (sepsis, vasopressors)

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 22: Prof. Xavier MONNET

3.5 L/min

PiCCO and EV1000 devices measure cardiac output by

arterial pressure curveanalysis

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 23: Prof. Xavier MONNET

PiCCO and EV1000 devices measure cardiac output by

inj

Blood temperature (Ts)

Ttm

cold bolus

calibrated by

transpulmonarythermodilution

arterial pressure curveanalysis

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 24: Prof. Xavier MONNET

Vigileo2

PiCCO

calibratedcardiac index

uncalibratedcardiac index

changes induced byvolume expansion (40 patients)

changes induced bynorepinephrine (40 patients)

Ability to track

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 25: Prof. Xavier MONNET

-15 0 15 30 45 60 75

-15

0

15

30

45

60

75

D CItd (%)

r = 0.78p < 0.05

PiCCO

r = -0.03p = NS

-15 0 15 30 45 60 75 90 105 120

-15

0

15

30

45

60

75

90

105

120

D CItd (%)

Vigileo2

Changes induced by

norepinephrine

Changes induced by

volume expansion

PiCCO

r = 0.72p < 0.05

-15 0 15 30 45 60 75 90 105 120

-15

0

15

30

45

60

75

90

105

120

D CIp

c (%

)

DCItd (%)

Vigileo2

r = 0.33p < 0.05

-15 0 15 30 45 60 75 90 105120

-15

0

15

30

45

60

75

90

105

120

D CIp

w (%

)

D CItd (%)

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 26: Prof. Xavier MONNET

51 pts, 401 measurementsVigileo2 vs.Vigileo3 vs. PAC

Vigileo3 is more accurate and as precise than Vigileo2

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 27: Prof. Xavier MONNET

33 patientsVigileo3 vs. esophageal DopplerHemodynamic challenges by phenylephrine, ephedrine and whole-body tilting

Which device for advanced monitoring?Ad

vanc

ed IC

U m

onito

ring

Page 28: Prof. Xavier MONNET

PA catheter

Which device for monitoring cardiac output?

PiCCO EV 1000

cardiac output cardiac output cardiac output

Adva

nced

ICU

mon

itorin

g

Page 29: Prof. Xavier MONNET

Context

Goals of monitoring

predict fluid responsiveness

precisely monitor the effects of therapy

fix some therapeutic goals

when shock persists after initial fluid therapy

assess the risk of fluid expansion

critically ill patients

Adva

nced

ICU

mon

itorin

g

Page 30: Prof. Xavier MONNET

PA catheter PiCCO EV 1000

cardiac output cardiac output cardiac output

SvO2ScvO2 ScvO2

How to assess the need for fluid?Ad

vanc

ed IC

U m

onito

ring

Page 31: Prof. Xavier MONNET

Context

Goals of monitoring

predict fluid responsiveness

precisely monitor the effects of therapy

fix some therapeutic goals

when shock persists after initial fluid therapy

assess the risk of fluid expansion

critically ill patients

Adva

nced

ICU

mon

itorin

g

Page 32: Prof. Xavier MONNET

PA catheter PiCCO EV 1000

cardiac output cardiac output cardiac output

PAOP

SvO2ScvO2 ScvO2

How to assess the need for fluid?

PPV, SVV,PLR test, EEO test

PPV, SVV,PLR test, EEO test

Adva

nced

ICU

mon

itorin

g

Page 33: Prof. Xavier MONNET

How to assess the need for fluid?Ad

vanc

ed IC

U m

onito

ring

Page 34: Prof. Xavier MONNET

EV 1000PA catheter PiCCO

cardiac output cardiac output cardiac output

PAOP

SvO2ScvO2 ScvO2

How to assess the need for fluid?

PPV, SVV,PLR test, EEO test

PPV, SVV,PLR test, EEO test

continuous continuous

Adva

nced

ICU

mon

itorin

g

Page 35: Prof. Xavier MONNET

venous return

How to assess the need for fluid?Ad

vanc

ed IC

U m

onito

ring

Page 36: Prof. Xavier MONNET

34 patients with acute circulatory failuremonitored by PiCCO device

-10

0

10

20

30

40

50

Effects of end-expiratory pause

on cardiac index

increase 5%Se = 91%Sp = 100 %

How to assess the need for fluid?Ad

vanc

ed IC

U m

onito

ring

RNR

Page 37: Prof. Xavier MONNET

How to assess the need for fluid?Ad

vanc

ed IC

U m

onito

ring

Page 38: Prof. Xavier MONNET

Context

Goals of monitoring

predict fluid responsiveness

precisely monitor the effects of therapy

fix some therapeutic goals

when shock persists after initial fluid therapy

assess the risk of fluid expansion

critically ill patients

Adva

nced

ICU

mon

itorin

g

Page 39: Prof. Xavier MONNET

EV 1000PA catheter PiCCO

cardiac output cardiac output cardiac output

PAOP

SvO2ScvO2 ScvO2

PPV, SVV,PLR test, EEO test

PPV, SVV,PLR test, EEO test

lung waterand lung permeability

lung waterand lung permeability

How to assess the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 40: Prof. Xavier MONNET

Pcap

lung water

normal permeability

very high permeability

Pcap

lungwater

How to assess the risk of volume expansion?

high permeability

Adva

nced

ICU

mon

itorin

g

Lung permeability

Page 41: Prof. Xavier MONNET

Lung water for estimating the risk of volume expansion?

Pcap

Lung water

normal permeability

very high permeability

Pcap

lungwater

lungwater

high permeability

Lung permeability

Adva

nced

ICU

mon

itorin

g

Page 42: Prof. Xavier MONNET

Cold bolus

PiCCO EV1000

Lung water for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 43: Prof. Xavier MONNET

validation in human beings→

Lung water for estimating the risk of volume expansion?

30 ptsEVLW measured by TPTD and by postmortem gravimetry

First validation of EVLW-TPTD evaluation in humans

Adva

nced

ICU

mon

itorin

g

Page 44: Prof. Xavier MONNET

Lung water for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 45: Prof. Xavier MONNET

Extra-vascular lung water and pulmonary vascular permeability index are independent prognostic factors in patients with acute respiratory distress syndrome

Jozwiak M, Silva S, Persichini R, Anguel N, Osman D, Richard C, Teboul JL, Monnet X

0

20

40

60

80

100

EVLWImax > 21 mL/kg EVLWImax ≤ 21 mL/kg

70%

42%

p = 0.0001

Day-28 mortality (%)

p value

Maximal blood lactate 0.81 (0.71 - 0.93) 0.002Mean PEEP 1.25 (1.07 - 1.47) 0.005

EVLWI max 0.94 (0.87 - 0.98) 0.01

SAPS II 0.97 (0.95 - 0.99) 0.02Mean fluid balance 0.9996 ( 0.9993 - 0.9999) 0.02Minimal P/F ratio 1.01 (1.00 - 1.02) 0.02Minimal pH 35.97 (0.47 - 2769.52) 0.10

Odds Ratio ( CI 95%)

200 pts with ARDSEVLW measured by PiCCO device

Lung water for estimating the risk of volume expansion?

submitted

Adva

nced

ICU

mon

itorin

g

Page 46: Prof. Xavier MONNET

PAOP group

EVLW group

Time (hours)

Cumulative fluid balance (input - output; L)7

3

1

5

-1

-3

-50 12 24 36 48 60 72

***

*

* p < 0.0001 vs time 0

Mitchell JP et al., Am Rev Respir Dis 1992

101 ARDS patientsrandomized to EVLW-guided management vs.PAOP-guided management

Lung water for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 47: Prof. Xavier MONNET

0

5

10

15

20

25

Ventilation days ICU days

PAOP Group

EVLW Group

* * Management of fluid therapy with :

functional benefit of lung water monitoring

Mitchell JP et al., Am Rev Respir Dis 1992

101 ARDS patientsrandomized to EVLW-guided management vs.PAOP-guided management

Lung water for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 48: Prof. Xavier MONNET

Lung water for estimating the risk of volume expansion

Pcap

Lung water

normal permeability

very high permeability

Pcap

lungwater

lungwater

high permeability

Lung permeability

Adva

nced

ICU

mon

itorin

g

Page 49: Prof. Xavier MONNET

lung water

cold bolus pulmonary blood volume

pulmonary vascularpermeability index =PVPI

PiCCO EV1000

Lung permeability for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 50: Prof. Xavier MONNET

0123456789

10PVPI

ALI/ARDS Hydrostaticpulmonary edema

*

Cut-off : 3

Se = 85 %

Sp = 100 %

48 patients with pulmonary edemainflammatory vs. hydrostatic discriminated by expertsPVPI by the PiCCO device

Lung permeability for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 51: Prof. Xavier MONNET

PVPI = 4 PVPI= 7

ARDS

AP = 90 / 40 mmHg

Cardiac index = 2.0 L/min/m2

PaO2/FiO2 = 180 mmHg

PLR test : positive

ARDS

AP = 90 / 40 mmHg

Cardiac index = 2.0 L/min/m2

PaO2/FiO2 = 180 mmHg

PLR test : positive

volume expansion volume expansion

vasopressors?

Lung permeability for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 52: Prof. Xavier MONNET

PA catheter PiCCO EV 1000

cardiac output cardiac output cardiac output

PAOP

SvO2ScvO2 ScvO2

PPV, VVE,PLR test, EEO test

PPV, VVE,PLR test, EEO test

lung waterand lung permeability

lung waterand lung permeability

Lung permeability for estimating the risk of volume expansion?Ad

vanc

ed IC

U m

onito

ring

Page 53: Prof. Xavier MONNET

APCVP

PiCCO

EsophagealDoppler

Echo

ProAQT/PulsioFlex

PAC

FloTrac/vigileo

Nexfin

Differents monitoring devicesDifferent indications !

Page 54: Prof. Xavier MONNET

Arterial pressure

Esophageal Doppler

Flotrac/VigileoPulsioflex

LidCOrapid

PA catheter

CVP

PiCCOEV 1000

ICU monitoring

OR monitoring

Basic monitoring Advanced monitoring